Litigation Details for Allergan, Inc. v. Mankind Pharma Ltd. (D. Del. 2023)
✉ Email this page to a colleague
Allergan, Inc. v. Mankind Pharma Ltd. (D. Del. 2023)
| Docket | ⤷ Start Trial | Date Filed | 2023-03-13 |
| Court | District Court, D. Delaware | Date Terminated | 2024-10-29 |
| Cause | 35:271 Patent Infringement | Assigned To | John F. Murphy |
| Jury Demand | None | Referred To | |
| Patents | 7,851,504; 8,338,479 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Allergan, Inc. v. Mankind Pharma Ltd.
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for Allergan, Inc. v. Mankind Pharma Ltd. (D. Del. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-03-13 | External link to document | |||
| 2023-03-13 | 110 | Strike | invalidity contentions concerning U.S. Patent No. 7,851,504 (the “’504 patent”). On September 27, 2023, Mankind…invalidity contentions concerning U.S. Patent No. 7,851,504 are STRICKEN. …the validity of the ’504 patent, that “all discovery pertinent only to patent validity … is not relevant… 2023 29 October 2024 1:23-cv-00272 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-03-13 | 123 | Brief - Answering Brief in Opposition | prolong the life of an invalid patent, U.S. Patent No. 7,851,504 (the “’504 patent”) and prevent generic competition…permitted to challenge the patent for DP. Maintaining the suit of an invalid patent does not 1 In the meet…Mankind’s invalidity argument based on double patenting (“DP”). By precluding this argument, Plaintiffs… to include an affirmative defense of double patenting. (D.I. 92) (“Motion to Vacate”). Mankind will …litigation even if a change to DP law renders the ’504 patent invalid. But if the expected change in DP is announced | External link to document |
| 2023-03-13 | 126 | Order AND ~Util - Terminate Motions | or enforceability of any claim of [U.S. Patent No. 7,851,504] in this action.” DI 60 at 2. 2.…and argue that the 504 patent is invalid due to obviousness-type double patenting over the later-filed,…the law that will render the 504 patent invalid for double patenting. DI 108 at 1–2, 7. Mankind admits…later-expiring patent. What purpose of the judicially created doctrine of obviousness-type double patenting — especially…history of obviousness-type double patenting is a graveyard of patents invalidated by surprising (to me, | External link to document |
| 2023-03-13 | 136 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,851,504. (vfm) 29 October…HOLDER OF PATENT OR TRADEMARK TRADEMARK NO. OR TRADEMARK 1 US 7,851,504 … G ✔ Patents. ( G the patent action involves 35 U.S.C. § 292.): DOCKET…Mankind Pharma Ltd. PATENT OR DATE OF PATENT … G Other Pleading PATENT OR DATE OF PATENT | External link to document |
| 2023-03-13 | 4 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,851,504. (vfm) (Entered: … 2023 29 October 2024 1:23-cv-00272 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
